Graft Versus Host Disease (GVHD) Therapeutics

Jan. 2, 2012 - PRLog -- GlobalData estimates that the global Graft Versus Host Disease (GVHD) therapeutics market was worth
$261.6m in 2010 and is forecast to grow at a Compound Annual Growth Rate (CAGR) of 11.3% to reach $615.1m by 2018. This moderate growth is primarily attributed to the strong pipeline landscape, increase in the number of Hematopoietic Stem Cell Transplants (HSCTs) and the launch of new first-in-class drugs with improved safety and efficacy profiles.

GlobalData analysis shows that the current market landscape is weak as generic immunosuppressive agents are used off-label. These products have moderate levels of efficacy and safety and as a result,
GVHD remains a major cause of mortality following HSCT. The current market has significant unmet need and thus provides significant potential for pipeline drugs that are stronger in terms of efficacy and safety. However, considering the fact that a majority of the pipeline products are first-in-class but are Mesenchymal Stem Cell (MSC) therapies aimed primarily at the prevention of GVHD, the therapeutic market will continue to remain dominated by the existing drugs. If approved, these new therapies will create a new market.

HSCT is a treatment option for certain types of leukemia and lymphoma such as Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL) and Myelodysplastic Syndrome (MDS) when chemotherapy and/or radiation therapy fail. The past two decades have seen a gradual increase in the number of allogeneic HSCTs performed annually. The increasing incidence of leukemia has led to more elderly patients receiving reduced-intensity or non-myeloablative transplants because the risk of ALL, ALL and MDS increases in people above the age of 50 years. GVHD risk also increases with age, meaning that incidence is increasing and the market is growing.

For Sample Pages, please click or add the below link to your browser:
http://www.globaldata.com/reportstore/RequestSamplePages....

GlobalData, the industry analysis specialist, has released its new report, “Graft Versus Host Disease (GVHD) Therapeutics - Pipeline Assessment and Market Forecasts to 2018”. The report is an essential source of information and analysis on the global Graft Versus Host Disease (GVHD) Therapeutics market. The report identifies the key trends shaping and driving the global Graft Versus Host Disease (GVHD) Therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global Graft Versus Host Disease (GVHD) Therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.

For further details, please click or add the below link to your browser:
http://www.globaldata.com/reportstore/Report.aspx?ID=Graf...

Visit our report store: http://www.globaldata.com/reportstore

For more details contact:
pressreleases@globaldata.com
           
North America:    +1 646 395 5477
Europe:        +44 207 753 4299
           +44 1204 543 533
Asia Pacific:       +91 40 6616 6782

# # #

GlobalData is a global market intelligence services company providing information research and analysis products and services.